Johnson & Johnson reports two‑year IMAAVY data showing sustained disease control in adolescent gMG
- Vibrance‑MG adolescents at Week 108 showed mean MG‑ADL change −2.88 and QMG change −8.25 from baseline.
- Of six adolescent patients on corticosteroids at study entry, three reduced dose and one discontinued after two years on IMAAVY.
- A retrospective survey of 97 adult patients found fluctuating symptom control prompted discontinuation in 54.6%, and 62.9% switched to IMAAVY for a consistent treatment schedule.
- Following transition to IMAAVY, 73.2% were reported as much/very much improved and 76.4% reduced prednisone dose (5.5% discontinued).
Data presented
Johnson & Johnson presented 15 abstracts at the 2026 MGFA Scientific Session and AANEM Annual Meeting, including two‑year results from the Phase 2/3 Vibrance‑MG study in adolescents and a retrospective HCP survey on treatment transitions in adults with anti‑AChR+ or anti‑MuSK+ gMG.
Two‑year adolescent results
The Vibrance‑MG long‑term extension showed sustained disease control through Week 108 with mean changes from baseline of −2.88 points in MG‑ADL and −8.25 points in QMG; among six adolescents on corticosteroids at entry, three reduced dose and one discontinued after two years on IMAAVY. No new safety signals were identified and the adolescent safety profile was similar to that observed in adults.
HCP survey on treatment transitions
A retrospective, 21‑item electronic survey of U.S. neurology HCPs reported de‑identified data for 97 adults who switched from prior advanced therapies to IMAAVY. HCPs cited fluctuating symptom control as the leading reason for stopping prior therapy (54.6%), while preference for a consistent treatment schedule (62.9%) and hope for improved efficacy (56.7%) were top reasons for initiating IMAAVY. After switch, 73.2% were reported as “much improved” or “very much improved,” 76.4% reduced prednisone dose and 5.5% discontinued prednisone.
Study context, mechanism and approvals
IMAAVY (nipocalimab‑aahu) is an FcRn blocker designed to reduce circulating IgG antibodies. Vibrance‑MG (NCT05265273) is an open‑label study that enrolled seven participants aged 12–17 receiving IV nipocalimab every two weeks with primary endpoints at 24 weeks. IMAAVY is approved by the FDA and EMA for adults and pediatric patients 12 years and older with anti‑AChR or anti‑MuSK antibody‑positive gMG.
Source: J&J